MindRank Announces First Patient Dosed in Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001

2026-02-26 - 02:33

SHANGHAI, China, Feb. 25, 2026 (GLOBE NEWSWIRE) -- MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced that the first patient has been dosed in the Phase III clinical trial of MDR-001, its AI-designed oral small-molecule GLP-1 receptor agonist (GLP-1RA) for the treatment of obesity and type 2 diabetes in China. Read More